Photo-degradable micelles for co-delivery of nitric oxide and doxorubicin

Ding, Zhanling; He, Kewu; Duan, Yutian; Shen, Zhiqiang; Cheng, Jian; Zhang, Guoying; Hu, Jinming

doi:10.1039/d0tb00817f

Cited by 26 publications

(15 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incorporating polymers into a NO release platform allows delivering NO in a more continuous manner, including through micelles, dendrimers, star-shaped polymers, and polymeric nanoparticles [90]. Micelles use amphiphilic polymers to synthesize concentration-dependent structures through hydrophilic or hydrophobic interactions but have a low encapsulation efficiency [36,[90][91][92]. Dendrimers are three-dimensional hyperbranched globular nanopolymeric architectures with the advantages of a narrow polydispersity index, controllable structure, and the availability of multiple functional groups at the periphery [93][94][95].…”

Section: Manipulating Nitric Oxide Delivery Process With No Release Platformmentioning

confidence: 99%

Delivery of Nitric Oxide in the Cardiovascular System: Implications for Clinical Diagnosis and Therapy

Zhang

Chen

et al. 2021

IJMS

View full text Add to dashboard Cite

Nitric oxide (NO) is a key molecule in cardiovascular homeostasis and its abnormal delivery is highly associated with the occurrence and development of cardiovascular disease (CVD). The assessment and manipulation of NO delivery is crucial to the diagnosis and therapy of CVD, such as endothelial dysfunction, atherosclerotic progression, pulmonary hypertension, and cardiovascular manifestations of coronavirus (COVID-19). However, due to the low concentration and fast reaction characteristics of NO in the cardiovascular system, clinical applications centered on NO delivery are challenging. In this tutorial review, we first summarized the methods to estimate the in vivo NO delivery process, based on computational modeling and flow-mediated dilation, to assess endothelial function and vulnerability of atherosclerotic plaque. Then, emerging bioimaging technologies that have the potential to experimentally measure arterial NO concentration were discussed, including Raman spectroscopy and electrochemical sensors. In addition to diagnostic methods, therapies aimed at controlling NO delivery to regulate CVD were reviewed, including the NO release platform to treat endothelial dysfunction and atherosclerosis and inhaled NO therapy to treat pulmonary hypertension and COVID-19. Two potential methods to improve the effectiveness of existing NO therapy were also discussed, including the combination of NO release platform and computational modeling, and stem cell therapy, which currently remains at the laboratory stage but has clinical potential for the treatment of CVD.

show abstract

Section: Manipulating Nitric Oxide Delivery Process With No Release Platformmentioning

confidence: 99%

Delivery of Nitric Oxide in the Cardiovascular System: Implications for Clinical Diagnosis and Therapy

Zhang

Chen

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Last but not least, the combination of CO and conventional antibiotics has shown an increased antimicrobial performance of antibiotics, similar to the synergistic effects of gaseous signaling molecules and other therapeutic agents such as antitumor agents [67] . The enhanced antibacterial properties and the reversal of antibiotic resistance shed light on the development of new antibacterial agents, which is highly desirable in the post‐antibiotic era.…”

Section: Discussionmentioning

confidence: 99%

Recent Advances on Carbon Monoxide Releasing Molecules for Antibacterial Applications

Cheng

2021

ChemMedChem

Self Cite

View full text Add to dashboard Cite

Carbon monoxide (CO) has been known as an endogenous signaling molecule in addition to an air pollutant. It plays a critical role in many physiological and pathological processes. Therefore, CO has been recognized as a potent therapeutic agent for the treatment of numerous diseases such as cancers, rheumatoid arthritis, and so on. Instead of direct CO inhalation, two main categories of CO‐releasing molecules (CORMs) (i. e., metal carbonyls and nonmetallic CO donors) have been developed to safely and locally deliver CO to target tissues. In this minireview, we summarize the recent achievements of CORMs on antibacterial applications. It appears that the antibacterial activity of CORMs is different from CO gas, which is tightly correlated to not only the types of CORMs applied but also the tested bacterial strains. In some circumstances, the antibacterial mechanisms are debated and need to be clarified. We hope more attention can be paid to this emerging field and new antibacterial agents with a low risk of drug resistance can be developed.

show abstract

“…Incorporating polymers into NO releasing platform allows transporting NO in a more continuous manner, including micelles, dendrimers, star-shaped polymers, and polymeric nanoparticles [128]. Micelles use amphiphilic polymers to synthesize concentration-dependent structures through hydrophilic or hydrophobic interactions, but have low encapsulation efficiency [128][129][130][131]. Dendrimers are three-dimensional hyperbranched globular nanopolymeric architectures with advantages of narrow polydispersity index, controllable structure and availability of multiple functional groups at the periphery [132][133][134].…”

Section: The Overview Of Nitric Oxide Releasing Platform and Its Limitationsmentioning

confidence: 99%

The Delivery of Nitric Oxide in the Cardiovascular System: Implication for Clinical Diagnosis and Therapy

Ma¹,

Zhang²,

Chen³

et al. 2021

Preprint

View full text Add to dashboard Cite

Nitric oxide (NO) is a key molecule in cardiovascular homeostasis and its abnormal delivery is highly associated with the occurrence and development of cardiovascular disease (CVD). The assessment and manipulation of NO delivery is crucial to the diagnosis and therapy of CVD, such as endothelial dysfunction, atherosclerotic progression, pulmonary hypertension, and cardiovascular manifestations of Coronavirus (COVID-19). However, due to the low concentration and fast reaction characteristics of NO in cardiovascular system, the clinical applications centered on the NO delivery are challenging. In this tutorial review, we first summarized the methods to estimate the in vivo NO delivery process based on the clinical images and mathematical modeling to assess the endothelial function and vulnerability of atherosclerotic plaque. Then, the emerging bioimaging technologies that have the potential to directly measure the arterial NO concentration were discussed, including the Raman spectroscopy and electrochemical sensor. Aside from the diagnostic methods, therapies aimed at controlling NO delivery to regulate CVD were reviewed, including the inhaled NO therapy to treat the pulmonary hypertension and COVID-19, stem cell therapy and NO-releasing platform to treat endothelial dysfunction and atherosclerosis.

show abstract

Photo-degradable micelles for co-delivery of nitric oxide and doxorubicin

Abstract: Photo-degradable triblock copolymers enable the co-delivery of nitric oxide and doxorubicin exerting an improved therapeutic effect.

Cited by 26 publications

References 61 publications

Delivery of Nitric Oxide in the Cardiovascular System: Implications for Clinical Diagnosis and Therapy

Delivery of Nitric Oxide in the Cardiovascular System: Implications for Clinical Diagnosis and Therapy

Recent Advances on Carbon Monoxide Releasing Molecules for Antibacterial Applications

The Delivery of Nitric Oxide in the Cardiovascular System: Implication for Clinical Diagnosis and Therapy

Contact Info

Product

Resources

About